Literature DB >> 9517366

Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

A Sharma1, W J Jusko.   

Abstract

This review describes four basic physiologic indirect pharmacodynamic response (IDR) models which have been proposed to characterize the pharmacodynamics of drugs that act by indirect mechanisms such as inhibition or stimulation of the production or dissipation of factors controlling the measured effect. The principles underlying IDR models and their response patterns are described. The applicability of these basic IDR models to characterize pharmacodynamic responses of diverse drugs such as inhibition of gastric acid secretion by nizatidine and stimulation of MX protein synthesis by interferon alpha-2a is demonstrated. A list of other uses of these models is provided. These models can be readily extended to accommodate additional complexities such as nonstationary or circadian baselines, equilibration delay, depletion or accumulation of a precursor pool, sigmoidicity, or other mechanisms. Indirect response models which have a logical mechanistic basis account for time-delays in many responses and are widely applicable in clinical pharmacology.

Entities:  

Mesh:

Year:  1998        PMID: 9517366      PMCID: PMC1873365          DOI: 10.1046/j.1365-2125.1998.00676.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

2.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

3.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

5.  Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin.

Authors:  R Nagashima; R A O'Reilly; G Levy
Journal:  Clin Pharmacol Ther       Date:  1969 Jan-Feb       Impact factor: 6.875

6.  Convergence of direct and indirect pharmacodynamic response models.

Authors:  W J Jusko; H C Ko; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

7.  The time course of delivery of furosemide into urine: an independent determinant of overall response.

Authors:  S Kaojarern; B Day; D C Brater
Journal:  Kidney Int       Date:  1982-07       Impact factor: 10.612

8.  Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate.

Authors:  S Rohatagi; A Bye; C Falcoz; A E Mackie; B Meibohm; H Möllmann; H Derendorf
Journal:  J Clin Pharmacol       Date:  1996-10       Impact factor: 3.126

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.

Authors:  K A Nieforth; R Nadeau; I H Patel; D Mould
Journal:  Clin Pharmacol Ther       Date:  1996-06       Impact factor: 6.875

View more
  64 in total

1.  Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Characterization of pharmacodynamic recession slopes for direct and indirect response models.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

3.  Indirect-response modeling of desmopressin at different levels of hydration.

Authors:  T Callréus; J Odeberg; S Lundin; P Höglund
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

4.  Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine.

Authors:  I Perlstein; D Stepensky; D Sapoznikov; A Hoffman
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

5.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

6.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

Review 7.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

Review 8.  Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.

Authors:  Robert M Straubinger; Wojciech Krzyzanski; Crystal M Francoforte; Jun Qu
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

Review 9.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; R L Webb; D Feldman; F Fu; M Beil; L Jin; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.